EPO Knocks Down Trio of Geron Patent Claims

Law360, New York (June 14, 2006, 12:00 AM EDT) -- In another blow to Geron Corp., the European Patent Office has ruled in favor of Danish pharmaceutical giant Pharmexa A/S and invalidated three claims of the U.S. biotechnology company’s European patent related to telomerase-targeted cancer vaccines.

On Wednesday, Pharmexa announced that the EPO had rejected a trio of Geron’s patent claims involving peptide vaccines against telomerase, an enzyme that adds specific DNA sequence repeats to the ends of DNA strands.

"It was a clear decision, solidly based on the arguments Pharmexa has presented,” said Jakob Schmidt,...
To view the full article, register now.